La maladie d’Alzheimer et le cannabis médical Kalapa Clinic, Barcelone, Espagne By Alexandra|24,09, 2020 La maladie d’Alzheimer neurodégénérative est la forme la plus courante de démence, qui survient généralement chez les personnes âgées de plus de 65 ans. Environ 24 millions de personnes dans le monde souffrent de cette maladie, qui porte le nom du médecin Alois Alzheimer. Il a décrit la maladie pour la première fois en 1906. La maladie d’Alzheimer : Que se passe-t-il dans le cerveau? Chez les patients atteints de la maladie d’Alzheimer, les cellules nerveuses du cerveau meurent progressivement, ce qui entraîne un rétrécissement du cerveau pouvant aller jusqu’à 20 [...]
Lire la suiteNeurological Manifestations Associated with Synthetic Cannabinoid Use - A Case Series Marwa Elnazeir, Siddharth Narayanan, Pradeepthi Badugu, Abid Hussain, Cody B. Stephens, Riwaj Bhagat, Christopher M. Jones, Wei Liu, Alexi R. Hernandez, Kerri S. Remmel and Adriana E. Palade The Open Neurology Journal, 2020, 14, 53-58. Doi : 10.2174/1874205X02014010053 Abstract : Background : Synthetic Cannabinoid (SC) use has emerged as a growing public health threat in the United States. Several unexpected cases, presenting with a constellation of unrelated symptoms, but all having toxicity linked to SC use, have been reported in the last decade (2010-2019). Methods : We report a cluster of several independent cases where patients were [...]
Lire la suitePrescription of a THC/CBD-Based Medication to Patients with Dementia : A Pilot Study in Geneva Barbara Broers, Zacharie Patà, Aline Mina, James Wampfler, Christian de Saussure, Sophie Pautex Medical Cannabis & Cannabinoids, 2019, 2, 56–59 Doi : 10.1159/000498924 Abstract Background : Dementia is increasing worldwide. No effective medication is currently available for the treatment of the underlying disease and accompanying behavioral symptoms. Cannabinoids might have a beneficial effect, but clinical studies with (low-dose) synthetic THC have not been conclusive. Objective : To test the acceptability, practical aspects, and clinical outcomes of the introduction of a THC/ CBD-based oral medication in severely demented patients in a specialized [...]
Lire la suite